Skip to content
Screener

Xencor XNCR Restricted Cash

Restricted Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.2M-48.5%
Janux Therapeutics logo
Janux TherapeuticsJANX
$816K0.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$25M0.0%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$858K0.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$49K+145%
Regenxbio logo
RegenxbioRGNX
$225K—

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The source filing: Xencor’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056

FAQ

What is Xencor's restricted cash?
Xencor (XNCR) reported restricted cash of $191K in Q2 2026.
How has Xencor's restricted cash changed year-over-year?
Xencor's restricted cash decreased by 33.2% year-over-year, from $286K to $191K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Xencor's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude